Skip to main content

OraSure Tech Value Stock - Dividend - Research Selection

OraSure Tech

ISIN: US68554V1089, WKN: 881351

Market price date: 27.05.2021
Market price: 9,73 USD

OraSure Tech Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2021
Cash flow
Net operating cash flow 5.807.000
Capital Expenditures -26.674.000
Free cash flow -20.867.000
Balance sheet
Total Equity 398.571.000
Liabilities & Shareholders equity 454.472.000
Income statement
Net income -14.922.000
Eps (diluted) -0,220
Diluted shares outstanding 71.738.000
Net sales/revenue 171.721.000

Fundamental ratios calculated on: 27-05-2021

Key figures 27-05-2021
Cash flow
P/C 118,47
P/FC -33,45
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization687.967.424,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split1987-04-08,3.0000/1.0000

Description of the company

OraSure Technologies, Inc., is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company´s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company´s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. The Company operates in two segments: OraSure business and DNAG. On August 17, 2011, the Company completed the acquisition of DNA Genotek Inc. (DNAG).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,